Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients.

Sarah Goldman-Mazur,Artur Jurczyszyn,Jorge J. Castillo,Anna Waszczuk-Gajda,Norbert Grzasko,Jakub Radocha,Max Bittrich,K. M. Kortüm,Alessandro Gozzetti,Lidia Usnarska-Zubkiewicz,Julio Davila Valls,David Jayabalan,Ruben Niesvizky,Julia Kelman,Daniel Coriu,Laura Rosiñol,Łukasz Szukalski,Verónica González-Calle,Maria-Victoria Mateos,Krzysztof Jamroziak,Iwona Hus,Irit Avivi,Yael C Cohen,Piotr Mazur,Anna Suska,Aimee Chappell,Deepu Madduri,Saurabh Chhabra,Ariel Kleman,Parameswaran Hari,Michel Delforge,Pawel Robak,Massimo Gentile,Izabela Kozłowska,Stuart L. Goldberg,Jacek Czepiel,Monika Długosz-Danecka,Rebecca Silbermann,Adam J. Olszewski,Peter Barth,Gábor Mikala,Chor S. Chim,David H. Vesole

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients.

2020

The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 25...

Keywords:

Chromosomal translocation
Sample size determination
Diabetes mellitus
Immunology
Medicine
Oncology
Multiple myeloma
Internal medicine
newly diagnosed
large group
small sample

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations